Aurobindo Pharma’s wholly owned subsidiary, Eugia Pharma Specialities Limited, has commercially launched Pomalidomide Capsules (1 mg, 2 mg, 3 mg, and 4 mg) in the United States.

The product serves as the generic equivalent to Pomalyst by BMS Pharmaceuticals Corp.

As a First-to-File (FTF) applicant, Eugia is positioned for early commercial presence in a market valued at approximately $3.3 billion as of January 2026. Production is centralized at the Eugia Unit-I facility.

This immunomodulatory drug is primarily used to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately US$ 3.3 billion in the U.S. Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.